March 17, 2025
The Phase II RESCUE trial subsequently evaluated targeting the more downstream IL-6 with ziltivekimab in participants with CKD and elevated high-sensitivity CRP (hsCRP) [83]
Side Effects: fatigue, weakness, lightheadedness or dizziness, headache, nausea or vomiting, diarrhea, vision changes, joint pain, difficulty falling or staying asleep, swelling, numbness or tingling in upper or lower extremities, shortness of breath, syncope, chest pain, significant bradycardia, hives, swelling of face, lips, tongue, or throat
For standard insulin syringes, dead space is roughly 0.05 to 0.07 mL
(2026) Semaglutide use is associated with neuromuscular junction degradation in older adults with type II diabetes mellitus
Even with comparable weight changes, the pair-feeding group did not receive the same cartilage protection, suggesting a weight-loss-independent effect on the joint itself